Your session is about to expire
← Back to Search
MARVIN Chatbots for Breast Cancer
N/A
Recruiting
Led By Bertrand Lebouché, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up once every 3 months within 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to expand the use of the MARVIN chatbot to other health areas like breast cancer and different populations like pharmacists. They will use a flexible trial design to test different interventions and may
Who is the study for?
This trial is for adults over 18 who speak English or French, can consent to participate, and have access to a device with internet. They must be willing to use Facebook Messenger-based chatbots and accept Facebook's privacy policies.
What is being tested?
The study tests different MARVIN chatbots (MARVIN, MARVIN-Pharma, MARVINA, MARVIN-CHAMP) designed for various health conditions like breast cancer and HIV. It uses an adaptive platform trial design allowing changes based on early results.
What are the potential side effects?
Since this trial involves informational chatbots rather than medical treatments, traditional side effects are not applicable. However, participants may experience issues related to data privacy or emotional discomfort from discussing health conditions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ once every 3 months within 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~once every 3 months within 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Acceptability E-Scale (AES)
Change in Acceptability E-Scale (AES) over 12 months
Change in Compatibility Subscale over 12 months
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: MARVINA: a Chatbot for Breast Cancer PatientsExperimental Treatment1 Intervention
Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
Group II: MARVIN: a Chatbot for HIV patientsExperimental Treatment1 Intervention
Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
Group III: MARVIN: a Chatbot for Community PharmacistsExperimental Treatment1 Intervention
Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
Group IV: MARVIN CHAMP: a Chatbot for Pediatric Infectious ConditionsExperimental Treatment1 Intervention
Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)OTHER
380 Previous Clinical Trials
131,189 Total Patients Enrolled
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,557 Total Patients Enrolled
Bertrand Lebouché, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
3 Previous Clinical Trials
155 Total Patients Enrolled